Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00476086 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00476086 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT00476086, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the feasibility and safety of giving the combination of oxaliplatin and gemcitabine followed by radiation therapy and to learn whether or not this drug combined with radiation therapy works in treating women with Mullerian tumors of the uterus.
Interventions
- DRUG Oxaliplatin
- DRUG Gemcitabine
- RADIATION Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00476086
The ClinicalTrials.gov registry entry for NCT00476086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oxaliplatin is the first listed.
NCT00476086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00476086 about?
NCT00476086 is a clinical study titled "Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus". The purpose of this research study is to determine the feasibility and safety of giving the combination of oxaliplatin and gemcitabine followed by radiation therapy and to learn whether or not this drug combined with radiation therapy works in treating women with Mullerian tumors of the uterus.
What is the current status of trial NCT00476086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2006-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00476086?
The interventions under investigation include: Oxaliplatin (DRUG), Gemcitabine (DRUG), Radiation (RADIATION).
Who is sponsoring clinical trial NCT00476086?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.